Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038974 · ClinicalTrials.gov registry record · Phase 3
Hepatitis C Antiviral Resistance in African-Americans
A Phase 3 study of Hepatitis C, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
- 401
- Enrollment target
- 8
- Study locations
NCT00038974 is a Phase 3 study of Hepatitis C that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 401 participants, below the 1,886-participant average among 106 other Hepatitis C trials with a reported enrollment target (79% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT00038974, a Phase 3 study of Hepatitis C, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 401 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied.
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG peginterferon alfa-2a
Study Locations (8)
California
- University of California, San Francisco - San Francisco
Florida
- University of Miami School of Medicine - Miami
Illinois
- Rush University - Chicago
Maryland
- University of Maryland School of Medicine - Baltimore
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Michigan
- University of Michigan Medical Center - Ann Arbor
New York
- New York-Presbyterian Medical Center - New York
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 401 participants |
| Start Date | 2002-08 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038974
The ClinicalTrials.gov registry entry for NCT00038974 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 401 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,886-participant average among 106 other Hepatitis C trials with a reported enrollment target (79% lower). The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Ribavirin is the first listed.
NCT00038974 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00038974 about?
NCT00038974 is a clinical study titled "Hepatitis C Antiviral Resistance in African-Americans". This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for diffe...
What is the current status of trial NCT00038974?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 401 participants. The study started on 2002-08. Estimated completion is 2005-11.
What conditions does trial NCT00038974 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00038974?
The interventions under investigation include: Ribavirin (DRUG), peginterferon alfa-2a (DRUG).
Who is sponsoring clinical trial NCT00038974?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00038974 being conducted?
This trial has 8 study locations across California, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
COMPLETED · Phase 3
-
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
COMPLETED · Phase 3
-
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
COMPLETED · Phase 3
-
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 3
-
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
COMPLETED · Phase 3
-
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.